Larimar jumps on FDA's 'breakthrough' tag for neurological disorder therapy

Larimar Therapeutics

24/02/2026 13:34

** Shares of therapy developer Larimar Therapeutics LRMR.O jump 32% to $3.71 premarket

** Co says the U.S. FDA granted a breakthrough designation for its experimental therapy nomlabofusp

** A breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need

** Nomlabofusp is a protein replacement therapy for the treatment of adults and children with the neurodegenerative disorder, Friedreich's ataxia

** Co plans to submit marketing application for nomlabofusp by June

** Up to last close, stock down 26.3% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))